Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis

Company Overview

Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) is a clinical-stage specialty pharmaceutical company dedicated to the research, development and manufacturing of vaccines and injectable therapeutics. Headquartered in Fort Lauderdale, Florida, the company leverages proprietary formulation and drug‐delivery platforms to enhance the stability, bioavailability and tolerability of its product candidates. Virpax’s integrated model spans early-stage discovery through cGMP manufacturing, enabling seamless progression from laboratory proof‐of‐concept to large-scale production.

Virpax’s pipeline encompasses a range of vaccine candidates targeting diseases such as rabies, herpes zoster and other infectious threats. Its proprietary adjuvant systems and lipid-based delivery technologies are designed to optimize immune responses while minimizing reactogenicity. In addition to vaccines, the company develops specialty injectable formulations for small molecules and biologics, addressing challenges related to solubility, absorption and patient compliance. Virpax advances its programs through collaborations with academic institutions, government agencies and contract development organizations, reinforcing its focus on both endemic and emerging health risks.

Since its founding, Virpax has invested in scalable U.S. manufacturing capabilities that adhere to current Good Manufacturing Practices. The company’s strategic emphasis on vaccine innovation and formulation expertise positions it to serve domestic and selected international markets. As Virpax progresses its pipeline through preclinical and clinical milestones, its leadership continues to pursue partnerships and licensing opportunities to accelerate the development and commercialization of its vaccine and injectable portfolios.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.0001 to $0.0111
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 1,231 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 8/01/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:VRPX
• CIK: 1708331
• Web: www.virpaxpharma.com
• Phone: 610-727-4597
• Fax: N/A
• Employees: 7
• Year Founded: 2017

Profitability

• EPS (Trailing Twelve Months): ($123.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.19 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,554.34%
• Return on Assets: -338.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.13
• Quick Ratio: 0.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.65 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,242,000
• Free Float: 4,707,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -16.52